A Case of Marburg Variant Multiple Sclerosis Treated With Rituximab.

Melanie Khamlong, Aishwarya Saripalli, Noah Yan, Anthony Bettencourt, Katayoun Sabetian

Abstract readCase Reports

In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Melanie KhamlongInternal Medicine, University of California, Los Angeles (UCLA) - Kern Medical, Bakersfield, USA.

Aishwarya SaripalliInternal Medicine, University of California, Los Angeles (UCLA) - Kern Medical, Bakersfield, USA.

Noah YanNeurology, University of California, Los Angeles (UCLA) - Kern Medical, Bakersfield, USA.

Anthony BettencourtNeurology, University of California, Los Angeles (UCLA) - Kern Medical, Bakersfield, USA.

Katayoun SabetianNeurology, University of California, Los Angeles (UCLA) - Kern Medical, Bakersfield, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Marburg variant is a rare, monophasic form of multiple sclerosis (MS) characterized by an aggressive clinical course. Diagnosis is confirmed with brain MRI demonstrating multiple focal T2-hyperintense lesions and with histopathology. While there is no established standard of care, high-dose corticosteroids followed by immunosuppressive therapies have commonly been used. Rituximab has been reported in the treatment of two previously described cases. We report a case of a 59-year-old woman diagnosed with Marburg variant MS who was successfully treated with rituximab.

Indexed as

fulminant multiple sclerosisimmunosuppressant therapymarburg variantmultiple sclerosisrituximab

Identifiers

PMID40984929

DOI10.7759/cureus.90698

PMCPMC12450239

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.